|

CGT4255 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Cogent Biosciences, Inc.1

Indications

  • HER2 Overexpression1
  • ERBB2 Gene Amplification1
  • ERBB2 Altered Breast Cancer1
  • Advanced Solid Tumor, Adult1
  • HER21

Grand Rapids, Michigan1 trial

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

START Midwest

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.